Biotechnology firm Celcuity Inc. has initiated a Phase 1b/2 clinical trial, known as CELC-G-201, to test the efficacy and safety of gedatolisib combined with Nubeqa® (darolutamide).

Elevation Oncology, a company listed on the Nasdaq (ELEV), is advancing its Phase 1 clinical trial for EO-3021, a novel antibody drug conjugate (ADC), by expanding the study to include Japan.

The SCOPE 2024 conference, inaugurated by Fareed Melhem of Medidata Solutions, emphasized the significance of integrating patient care with clinical research.

San Diego-based PassPort Technologies, Inc. (PPTI) has launched a Phase 1 clinical trial in the United States for the Zolmitriptan PassPort® system, which employs a unique transdermal microporation system.

AI-driven drug discovery firm Expert Systems has reached a key milestone in collaboration with Eilean Therapeutics, having completed a Phase 1 clinical trial for lomonitinib, a targeted pan-FLT3/IRAK4 inhibitor.

Biodexa Pharmaceuticals PLC has reported encouraging preliminary results from a Phase I clinical trial for MTX110.

Frontier Medicines recently closed an $80 million Series C funding round, with plans to advance its novel KRAS blocker, FMC-376.

J INTS BIO has announced that the Phase 1/2 clinical trial of its new oral 4th generation EGFR TKI, named "JIN-A02," for treating non-small cell lung cancer (NSCLC).

AceLink Therapeutics has reported positive preliminary findings for AL01211, an oral medication being developed to treat Fabry and Type 1 Gaucher diseases.

Cynata Therapeutics Limited has released initial data from its Phase 1 clinical trial of CYP-006TK for diabetic foot ulcers (DFU).

Kura Oncology has initiated its Phase 1 clinical trial, KOMET-008, which involves administering the menin inhibitor ziftomenib in tandem with gilteritinib.

Biora Therapeutics has achieved a significant milestone in its clinical trials for a novel drug-device combination, BT-600.